Loading patent…
AssigneeAbbott Laboratories
InventorsPATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, MARK HAYDEN, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, LISA ROBERTS-RAPP, JOHN C. RUSSELL, STEPHEN D. STROUPE
Estimating the term…
A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS 198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS 198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS 198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.
A method of detecting the presence of a target CS 198 polynucleotide in a test sample, comprising:
A method for detecting mRNA of CS 198 in a test sample, comprising:
A method of detecting a target CS 198 polynucleotide in a test sample suspected of containing said target, comprising:
A test kit useful for detecting CS 198 polynucleotide in a test sample, comprising a container containing at least one CS 198 polynucleotide having at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-27, and fragments or complements thereof.
A purified polynucleotide or fragment thereof derived from a CS 198 gene, wherein said polynucleotide is capable of selectively hybridizing to the nucleic acid of said CS 198 gene and has at least 50% identity with a polynucleotide selected from the group consisting of (a) SEQUENCE ID NOS 7-13 and complements thereof, (b) SEQUENCE ID NOS 15-26 and complements thereof, and (c) fragments of SEQUENCE ID NOS 7-26.
A recombinant expression system comprising a nucleic acid sequence that includes an open reading frame derived from CS 198 operably linked to a control sequence compatible with a desired host, wherein said nucleic acid sequence has at least 50% identity to a polynucleotide selected from the group consisting of SEQUENCE ID NOS 1-27, and fragments or complements thereof.
A CS 198 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of (a) SEQUENCE ID NOS 43-47, and (b) fragments of SEQUENCE ID NOS 42-47.
An antibody which specifically binds to at least one CS 198 epitope, wherein said CS 198 epitope is derived from an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NOS 42-47, and fragments thereof.
An assay kit for determining the presence of CS 198 antigen or anti-CS 198 antibody in a test sample, comprising a container containing a CS 198 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NOS 42-47, and fragments thereof.
An assay kit for determining the presence of CS 198 antigen in a test sample, comprising a container containing an antibody which specifically binds to a CS 198 antigen which comprises at least one CS 198 epitope.
A method for producing a polypeptide comprising at least one CS 198 epitope, said method comprising incubating host cells that have been transfected with an expression vector containing a polynucleotide sequence encoding a polypeptide, wherein said polypeptide comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NOS 42-47, and fragments thereof.
A method for detecting CS 198 antigen in a test sample suspected of containing said CS 198 antigen, comprising:
A method for detecting the presence of antibodies specific for a CS 198 antigen in a test sample suspected of containing such antibodies, said method comprising:
A cell transfected with a nucleic acid sequence encoding at least one CS 198 epitope, wherein said nucleic acid sequence is selected from the group consisting of SEQUENCE ID NOS 1-27, and fragments or complements thereof.
A method for producing antibodies which specifically bind to CS 198 antigen, comprising administering to an individual an isolated immunogenic polypeptide or fragment thereof in an amount sufficient to elicit an immune response, wherein said immunogenic polypeptide comprises at least one CS 198 epitope and has at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NOS 42-47, and fragments thereof.
A method for producing antibodies which specifically bind to CS 198 antigen, comprising administering to an individual a plasmid comprising a sequence which encodes at least one CS 198 epitope derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQUENCE ID NOS 42-47, and fragments thereof.
A composition of matter comprising a CS 198 polynucleotide or fragment thereof, wherein said polynucleotide has at least 50% identity with a polynucleotide selected from the group consisting of (a) SEQUENCE ID NOS 7-13 and complements thereof, (b) SEQUENCE ID NOS 15-26 and complements thereof, and (c) fragments of SEQUENCE ID NOS 7-26.
A composition of matter comprising a polypeptide containing at least one CS 198 epitope, wherein said polypeptide has at least 50% identity with a sequence selected from the group consisting of (a) SEQUENCE ID NOS 43-47, and (b) fragments of SEQUENCE ID NOS 42-47.
A gene, or a fragment thereof, which codes for a CS 198 protein which comprises an amino acid sequence having at least 50% identity with SEQUENCE ID NO 47.
A gene, or a fragment thereof, comprising DNA having at least 50% identity with SEQUENCE ID NO 26.
Dependencies are inferred from the claim text.